Stabilized interferon compositions

Details Stabilized interferon compositions Stabilized interferon compositions

2006-02-07

2006-02-07

Andres, Janet (Department: 1646)

Drug, bio-affecting and body treating compositions

Lymphokine

Interferon

C424S198100, C435S188000, C530S412000, C530S422000, C530S351000

Reexamination Certificate

active

06994847

ABSTRACT:
Stabilized pharmaceutical formulations comprising IFN-β and highly purified mannitol are provided. The highly purified mannitol stabilizes the compositions by reducing the formation of IFN-β adducts in comparison with IFN-β formulated with mannitol that has not been highly purified. Methods for increasing the stability of IFN-β or a variant thereof in a liquid or lyophilized composition and for increasing storage stability of such a composition are also provided.

REFERENCES:
patent: 4439181 (1984-03-01), Blackshear et al.
patent: 4462940 (1984-07-01), Hanisch et al.
patent: 4465622 (1984-08-01), Nobuhara et al.
patent: 4605555 (1986-08-01), Sato et al.
patent: 4605556 (1986-08-01), Sato et al.
patent: 4647454 (1987-03-01), Cymbalista
patent: 4675184 (1987-06-01), Hasegawa et al.
patent: 4808705 (1989-02-01), Ferris
patent: 4816440 (1989-03-01), Thomson
patent: 4992271 (1991-02-01), Hanisch et al.
patent: 5004605 (1991-04-01), Hershenson et al.
patent: 5104651 (1992-04-01), Boone et al.
patent: 5151265 (1992-09-01), Hwang-Felgner et al.
patent: 5183746 (1993-02-01), Shaked et al.
patent: 5573777 (1996-11-01), Serpelloni et al.
patent: 5609868 (1997-03-01), Lowther et al.
patent: 5643566 (1997-07-01), Hanisch et al.
patent: 5702699 (1997-12-01), Hanisch et al.
patent: 5762923 (1998-06-01), Gross et al.
patent: 5763409 (1998-06-01), Bayol et al.
patent: 0 080 879 (1986-10-01), None
patent: 0 217 645 (1987-04-01), None
patent: 0 270 799 (1988-06-01), None
patent: 0 164 397 (1990-07-01), None
patent: 0 410 207 (1991-01-01), None
patent: 0 410 207 (1991-01-01), None
patent: 0 133 767 (1991-04-01), None
patent: 0 477 386 (1992-01-01), None
patent: 0 215 658 (1994-06-01), None
patent: 0 736 303 (1996-10-01), None
patent: 0 759 775 (1997-03-01), None
patent: 0 875 253 (1998-11-01), None
patent: WO 90/06762 (1990-06-01), None
patent: WO 91/16038 (1991-10-01), None
patent: WO 95/31213 (1995-11-01), None
patent: WO 95/31479 (1995-11-01), None
Dubost, D.C. et al., “Characterization of a Solid State Reaction Product from a Lyophilized Formulation of a Cyclic Heptapeptide. A Novel Example of an Excipient-Induced Oxidation,”Pharmaceutical Research, Dec. 1996, pp. 1811-1814, vol. 13, No. 12.
Herberman et al., “Augmentation by Interferon of Human Natural and Antibody-Dependent Cell-Mediated Cytotoxicity”Nature277:221-223, Jan. 1979.
Williams et al., “Natural Ocurrence of 2-5A in Interferon-Treated EMC Virus-Infected L Cells”Nature282:582-586, 1979.
Anderson et al., “Specific Binding of125I-Human Inerferon-γ to High Affinity Receptors of Human Fibroblasts”J. Biological Chemistry 257(19) :11301-11304, 1982.
Fellous et al., “Interferon-Dependent Inductionof mRNA for the Major Histocampatibility Antigens in Human Fibroblasts and Lymphoblastoid Cells”Proc. Natl. Acad. Sci. 79: 3082- 3086, May, 1982.
Czarniecki et al., “Syneristic Antiviral and Antiproliferative Activities ofEscherichia coli-Derived Human Alpha, Beta, and Gamma Interferons”J. Virology 49(2) :490=496, Feb. 1984.
Mark et al., “Site-Specific Mutagenesis of the Human Fibroblast Interferon Gene”Proc. Natl. Acad. Sci. USA 81:5662-5666, Sep., 1984.

Affiliated with

Also associated with

Rating

Stabilized interferon compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Stabilized interferon compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stabilized interferon compositions will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3690475